Literature DB >> 20004201

Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer.

Ana González-García1, Jesús Sánchez-Ruiz, Juana M Flores, Ana C Carrera.   

Abstract

BACKGROUND & AIMS: A large body of evidence supports a correlation between inflammation and cancer, although the molecular mechanisms that govern this process are incompletely understood. Phosphatidylinositol 3-kinase (PI3K) is an enzyme that regulates the immune response and contributes to cell transformation in several tumor types. Here, we address the role of the PI3Kgamma isoform in inflammatory bowel disease and in the development of colitis-associated cancer.
METHODS: PI3Kgamma(-/-) and control mice were repeatedly treated with dextran sulfate sodium to induce chronic colitis and colitis-associated cancer. Colorectal tumor burden and colon inflammation were evaluated in these mice. Leukocyte populations in colon were characterized by flow cytometry analysis.
RESULTS: PI3Kgamma-deficient mice had a lower incidence of colitis-associated tumors, as well as reduced tumor multiplicity and smaller tumor size compared with controls. Reduced tumor development paralleled less colon inflammation in PI3Kgamma-deficient mice. Analysis of leukocyte populations in the colon of PI3Kgamma-deficient mice showed defective activation and infiltration of myeloid cells and defective recruitment of T cells to the colon compared with controls.
CONCLUSIONS: PI3Kgamma regulates the innate immune response in a murine model of ulcerative colitis, thereby controlling colon inflammation and tumor formation. 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20004201     DOI: 10.1053/j.gastro.2009.12.001

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  16 in total

1.  Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.

Authors:  Susan O'Brien; Manish Patel; Brad S Kahl; Steven M Horwitz; Francine M Foss; Pierluigi Porcu; Jeffrey Jones; Jan Burger; Nitin Jain; Kerstin Allen; Kerrie Faia; Mark Douglas; Howard M Stern; Jennifer Sweeney; Patrick Kelly; Virginia Kelly; Ian Flinn
Journal:  Am J Hematol       Date:  2018-10-20       Impact factor: 10.047

Review 2.  Intertwined regulation of angiogenesis and immunity by myeloid cells.

Authors:  Lee B Rivera; Gabriele Bergers
Journal:  Trends Immunol       Date:  2015-03-11       Impact factor: 16.687

3.  Inhibitor of PI3Kγ ameliorates TNBS-induced colitis in mice by affecting the functional activity of CD4+CD25+FoxP3+ regulatory T cells.

Authors:  R C Dutra; M Cola; D F P Leite; A F Bento; R F Claudino; A F Z Nascimento; P C Leal; J B Calixto
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 4.  Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms.

Authors:  Mihailo Miljanic; Anna Capasso; Todd A Triplett; S Gail Eckhardt; Kyaw L Aung
Journal:  J Immunother Precis Oncol       Date:  2020-02-10

Review 5.  Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer.

Authors:  Chiara Birtolo; Vay Liang W Go; Andrzej Ptasznik; Guido Eibl; Stephen J Pandol
Journal:  Pancreas       Date:  2016-01       Impact factor: 3.327

6.  PI3K/AKT signaling is essential for communication between tissue-infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer.

Authors:  Mohammad W Khan; Ali Keshavarzian; Elias Gounaris; Joshua E Melson; Eric C Cheon; Nichole R Blatner; Zongmin E Chen; Fu-Nien Tsai; Goo Lee; Hyunji Ryu; Terrence A Barrett; David J Bentrem; Philipp Beckhove; Khashayarsha Khazaie
Journal:  Clin Cancer Res       Date:  2013-03-13       Impact factor: 12.531

Review 7.  PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors.

Authors:  Francesco Dituri; Antonio Mazzocca; Gianluigi Giannelli; Salvatore Antonaci
Journal:  Clin Dev Immunol       Date:  2011-10-20

Review 8.  Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.

Authors:  Klaus Okkenhaug; Mariona Graupera; Bart Vanhaesebroeck
Journal:  Cancer Discov       Date:  2016-09-21       Impact factor: 39.397

Review 9.  The therapeutic implications of immunosuppressive tumor aerobic glycolysis.

Authors:  Bradley I Reinfeld; W Kimryn Rathmell; Tae Kon Kim; Jeffrey C Rathmell
Journal:  Cell Mol Immunol       Date:  2021-07-08       Impact factor: 11.530

10.  The role of phosphoinositide 3-kinase signaling in intestinal inflammation.

Authors:  Catherine M Cahill; Jack T Rogers; W Allan Walker
Journal:  J Signal Transduct       Date:  2012-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.